Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
NCT06093503Phase 3Withdrawn
- Lead sponsor
- AbbVie (Industry)
- Enrollment
- 0 (actual)
- Start date
- 31 May 2024
- Primary completion
- 11 Apr 2028 (estimated)
- Study completion
- 11 Apr 2028
- Last update posted
- 26 Jun 2024
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Telisotuzumab Vedotin Drug
- Osimertinib Drug
- Cisplatin Drug
- Carboplatin Drug
- Pemetrexed Drug
Conditions and primary outcome
- Non-Small Cell Lung Cancer
Primary outcome
PFS in the Population of Participants with no Central Nervous System (CNS) Metastases at Baseline (Up to Approximately 41 Months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06093503.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06093503 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.